Non-muscle Invasive Bladder Cancer Therapeutics and Forecast Market

List of Tables
Table 1. Non-muscle Invasive Bladder Cancer Therapeutics Market Opportunities & Trends in Global Market
Table 2. Non-muscle Invasive Bladder Cancer Therapeutics Market Drivers in Global Market
Table 3. Non-muscle Invasive Bladder Cancer Therapeutics Market Restraints in Global Market
Table 4. Key Players of Non-muscle Invasive Bladder Cancer Therapeutics in Global Market
Table 5. Top Non-muscle Invasive Bladder Cancer Therapeutics Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue Share by Companies, 2017-2022
Table 8. Global Companies Non-muscle Invasive Bladder Cancer Therapeutics Product Type
Table 9. List of Global Tier 1 Non-muscle Invasive Bladder Cancer Therapeutics Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Non-muscle Invasive Bladder Cancer Therapeutics Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type ? Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application ? Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region ? Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2023-2028
Table 30. F. Hoffmann-La Roche Ltd. Corporate Summary
Table 31. F. Hoffmann-La Roche Ltd. Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings
Table 32. F. Hoffmann-La Roche Ltd. Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn), (2017-2022)
Table 33. Bristol-Myers Squibb Company Corporate Summary
Table 34. Bristol-Myers Squibb Company Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings
Table 35. Bristol-Myers Squibb Company Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn), (2017-2022)
Table 36. AstraZeneca Corporate Summary
Table 37. AstraZeneca Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings
Table 38. AstraZeneca Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn), (2017-2022)
Table 39. Pfizer Inc. Corporate Summary
Table 40. Pfizer Inc. Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings
Table 41. Pfizer Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn), (2017-2022)
Table 42. GlaxoSmithKline plc. Corporate Summary
Table 43. GlaxoSmithKline plc. Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings
Table 44. GlaxoSmithKline plc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn), (2017-2022)
Table 45. Sanofi S.A. Corporate Summary
Table 46. Sanofi S.A. Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings
Table 47. Sanofi S.A. Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn), (2017-2022)
Table 48. Novartis AG Corporate Summary
Table 49. Novartis AG Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings
Table 50. Novartis AG Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn), (2017-2022)
Table 51. Eli Lilly and Company Corporate Summary
Table 52. Eli Lilly and Company Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings
Table 53. Eli Lilly and Company Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn), (2017-2022)
Table 54. Merck & Co. Corporate Summary
Table 55. Merck & Co. Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings
Table 56. Merck & Co. Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn), (2017-2022)
Table 57. Viventia Bio Inc. Corporate Summary
Table 58. Viventia Bio Inc. Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings
Table 59. Viventia Bio Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn), (2017-2022)
Table 60. Celgene Corporation Corporate Summary
Table 61. Celgene Corporation Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings
Table 62. Celgene Corporation Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn), (2017-2022)
Table 63. Spectrum Pharmaceuticals, Inc. Corporate Summary
Table 64. Spectrum Pharmaceuticals, Inc. Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings
Table 65. Spectrum Pharmaceuticals, Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn), (2017-2022)
Table 66. Herantis Pharma Plc. Corporate Summary
Table 67. Herantis Pharma Plc. Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings
Table 68. Herantis Pharma Plc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn), (2017-2022)
Table 69. Taris Biomedical LLC Corporate Summary
Table 70. Taris Biomedical LLC Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings
Table 71. Taris Biomedical LLC Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn), (2017-2022)
Table 72. Prometic Life Sciences Inc. Corporate Summary
Table 73. Prometic Life Sciences Inc. Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings
Table 74. Prometic Life Sciences Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn), (2017-2022)
Table 75. Telormediz S.A. Corporate Summary
Table 76. Telormediz S.A. Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings
Table 77. Telormediz S.A. Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn), (2017-2022)
Table 78. Heat Biologics Corporate Summary
Table 79. Heat Biologics Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings
Table 80. Heat Biologics Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn), (2017-2022)
Table 81. Altor BioScience Corporate Summary
Table 82. Altor BioScience Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings
Table 83. Altor BioScience Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn), (2017-2022)
Table 84. Ferring B.V. Corporate Summary
Table 85. Ferring B.V. Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings
Table 86. Ferring B.V. Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn), (2017-2022)
Table 87. Cold Genesys Inc. Corporate Summary
Table 88. Cold Genesys Inc. Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings
Table 89. Cold Genesys Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn), (2017-2022)
List of Figures
Figure 1. Non-muscle Invasive Bladder Cancer Therapeutics Segment by Type in 2021
Figure 2. Non-muscle Invasive Bladder Cancer Therapeutics Segment by Application in 2021
Figure 3. Global Non-muscle Invasive Bladder Cancer Therapeutics Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Non-muscle Invasive Bladder Cancer Therapeutics Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Non-muscle Invasive Bladder Cancer Therapeutics Revenue in 2021
Figure 8. By Type - Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share, 2017-2028
Figure 9. By Application - Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share, 2017-2028
Figure 10. By Region - Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share, 2017-2028
Figure 11. By Country - North America Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share, 2017-2028
Figure 12. US Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share, 2017-2028
Figure 16. Germany Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 17. France Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share, 2017-2028
Figure 24. China Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 28. India Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share, 2017-2028
Figure 30. Brazil Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share, 2017-2028
Figure 33. Turkey Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 37. F. Hoffmann-La Roche Ltd. Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Bristol-Myers Squibb Company Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. AstraZeneca Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Pfizer Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. GlaxoSmithKline plc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Sanofi S.A. Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Novartis AG Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Eli Lilly and Company Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. Merck & Co. Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 46. Viventia Bio Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 47. Celgene Corporation Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 48. Spectrum Pharmaceuticals, Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 49. Herantis Pharma Plc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 50. Taris Biomedical LLC Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 51. Prometic Life Sciences Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 52. Telormediz S.A. Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 53. Heat Biologics Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 54. Altor BioScience Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 55. Ferring B.V. Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 56. Cold Genesys Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)